– AXONIS secured an additional $5m in funding.
– The round was led by Alexandria Venture Investments with participation by R3 Bio, BoxOne Ventures and Civilization Ventures and two leading spinal cord injury non-profit foundations, the Christopher & Dana Reeve Foundation and Spinal Research.
– The new investment will support AXONIS’ next development phase as it continues to advance its novel neuromodulating technology into the clinic.
– The Company’s pipeline includes neuron-reviving therapeutics that enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration, restore excitation/inhibition balance and regenerate.
– The Company’s targeted indications include spinal cord injury and epilepsy, as well as broader neurodegenerative conditions.

– adyn, a precision medicine company, announced today that it has closed a $2.5m seed round of funding.
– The round was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC, and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis of Applied Intuition, and Ashley Mayer of Glossier.
– adyn uses proprietary hormone and genomic analyses to transform this selection process into a science and remove the guesswork.
– Using adyn’s precision medicine approach, patients and doctors will be able to personalize birth control selection, minimizing side effects ranging from annoyances like acne to life threatening conditions including blood clots and depression.

– Outpace Bio raised $30m in Series A funding.
– The round was led by ARTIS Ventures and Lyell Immunopharma, and joined by Abstract Ventures, Civilization Ventures, Mubadala Capital (the asset management arm of Mubadala Investment Company), Playground Global, Sahsen Ventures, and WRF Capital.
– Total funding to date is $30m.